✦ LIBER ✦

Results of xenogeneic I-RNA therapy in patients with metastatic renal cell carcinoma

✍ Scribed by Glenn Steele Jr; Bosco Shang Wang; Jerome P. Richie; Thomas Ervin; Ronald Yankee; John A. Mannick

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 287 KB
Volume: 47
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19810315)47:6<1286::aid-cncr2820470609>3.0.co;2-v

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infusional floxuridine-based therapy for

Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma

✍ David M. Reese; Michelle Corry; Eric J. Small 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

## BACKGROUND. The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional F

The role of radiation therapy in the man

The role of radiation therapy in the management of metastatic renal cell carcinoma

✍ Edward C. Halperin; Leon Harisiadis 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 2 views

A Phase II trial of bryostatin-1 for pat

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

✍ Lance Pagliaro; Danai Daliani; Robert Amato; Shi-Ming Tu; Donnah Jones; Terry Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

Granulocyte-macrophage–colony stimulatin

Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 1 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

Expression of calpain I messenger RNA in

Expression of calpain I messenger RNA in human renal cell carcinoma: Correlation with lymph node metastasis and histological type

✍ Christian Braun; Matthias Engel; Markus Seifert; Birgit Theisinger; Gerhard Seit 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 63 KB 👁 1 views

Calpain, also named CANP (for calcium-activated neutral protease), is an intracellular cytoplasmatic non-lysosomal cysteine endopeptidase that requires calcium ions for activity. Many substrates of the calpain isoenzymes, such as the transcription factors c-Fos and c-Jun, the tumor supressor protein